Magham Sai Varshini, Thaggikuppe Krishnamurthy Praveen, Shaji Neenu, Mani Lalithkumar, Balasubramanian Shivaramakrishnan
Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, India.
J Neurosci Res. 2021 Nov;99(11):2888-2905. doi: 10.1002/jnr.24933. Epub 2021 Sep 6.
Endocannabinoid system has been extensively studied in recent decades, particularly the cannabinoid receptors CB1 and CB2, due to their important role in neuroinflammation. Among these, CB2 has gained prominence due to its selective overexpression in glial cells during neuroinflammation. In contrast to CB1 agonists, CB2 agonists have no side effects such as ataxia, hypothermia, euphoria, psychological, or addiction liabilities. CB2 and its selective agonists' above-mentioned unique properties have become a research focus in neurodegenerative disorders such as Alzheimer's disease (AD). The review discusses the neuroprotective role of CB receptors, particularly CB2, in AD, as well as the significance and limitations of this research.
近几十年来，内源性大麻素系统得到了广泛研究，尤其是大麻素受体CB1和CB2，因为它们在神经炎症中发挥着重要作用。其中，CB2因其在神经炎症期间在胶质细胞中的选择性过表达而备受关注。与CB1激动剂不同，CB2激动剂没有诸如共济失调、体温过低、欣快感、心理问题或成瘾倾向等副作用。CB2及其选择性激动剂的上述独特性质已成为诸如阿尔茨海默病（AD）等神经退行性疾病的研究重点。本文综述讨论了CB受体，特别是CB2，在AD中的神经保护作用，以及该研究的意义和局限性。
